Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The event, set for June 27, 2024, will feature members of MindMed’s management team presenting their latest advancements in treating brain health disorders.
Webcast Access
A fireside chat webcast will be available on MindMed’s Investor Relations website starting at 7:00 AM ET on June 27, 2024. The presentation will remain accessible for replay on the website for up to 90 days following the event, providing a valuable resource for those interested in the company’s pioneering work.
About MindMed
MindMed is dedicated to developing novel product candidates that address brain health disorders. As a clinical-stage biopharmaceutical company, its mission is to lead the global market in innovative treatments that improve patient outcomes. MindMed’s pipeline includes a variety of product candidates targeting critical neurotransmitter pathways involved in brain health disorders, both with and without acute perceptual effects.
MindMed is publicly traded on NASDAQ under the symbol MNMD. The company continues to push the boundaries of biopharmaceutical research and development, aiming to unlock new therapeutic opportunities for patients worldwide.